DDInter1840 DDInter1576
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Regorafenib
Trabectedin {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Regorafenib
Trabectedin {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Regorafenib
Trabectedin {u} (Compound) causes {v} (Side Effect) Hyperbilirubinaemia
Hyperbilirubinaemia {u} (Side Effect) is caused by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) interacts with {v} (Gene) RAF1
RAF1 {u} (Gene) is bound by {v} (Compound) Regorafenib
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Regorafenib
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Trabectedin {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Regorafenib
Trabectedin {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Nervous system disorder {u} (Side Effect) is caused by {v} (Compound) Dolutegravir
Dolutegravir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Regorafenib
Trabectedin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Trabectedin (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Regorafenib (Compound)
Trabectedin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Regorafenib (Compound)
Trabectedin (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Sorafenib (Compound) and Sorafenib (Compound) resembles Regorafenib (Compound)
Trabectedin (Compound) causes Hyperbilirubinaemia (Side Effect) and Hyperbilirubinaemia (Side Effect) is caused by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) interacts with RAF1 (Gene) and RAF1 (Gene) is bound by Regorafenib (Compound)
Trabectedin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dapagliflozin (Compound) and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Regorafenib
Trabectedin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Trabectedin (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Regorafenib
Trabectedin (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Dolutegravir (Compound) and Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Regorafenib